biostudies-literaturePodzamczer DSPANISH AIDS Research NetworkISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regionalofab595https://www.ebi.ac.uk/biostudies/studies/S-EPMC8883591biostudies-literatureUnknown9(3)<h4>Background</h4>Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking.<h4>Methods</h4>Adult (>18 years old) human immunodeficiency virus-infected antiretroviral-naive patients (HLA-B∗5701 negative and hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally randomized to initiate D/C/F/TAF or dolutegravir/abacavir/lamivudine (DTG/3TC/ABC) after stratifying by VL and CD4 count. Clinical and analytical assessments were performed at weeks 0, 4, 12, 24, and 48. The primary endpoint was VOpen forum infectious diseasesDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).PMC8883591RD16/0025/0001Knobel HPodzamczer DFanjul FBernal ESanz JGomez CMican RRivero AMasia MVinuesa DLlibre JMMontero MPayeras ADomingo PRibera EFernandez GPortilla JMacias JTroya JTiraboschi JCaicedo AInciarte AMoreno SEstrada VVivancos MJNavarro-Alcaraz ACastro AMartinez EMorano LfalseDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).<h4>Background</h4>Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking.<h4>Methods</h4>Adult (>18 years old) human immunodeficiency virus-infected antiretroviral-naive patients (HLA-B∗5701 negative and hepatitis B virus negative), with viral load (VL) ≥500 c/mL, were centrally randomized to initiate D/C/F/TAF or dolutegravir/abacavir/lamivudine (DTG/3TC/ABC) after stratifying by VL and CD4 count. Clinical and analytical assessments were performed at weeks 0, 4, 12, 24, and 48. The primary endpoint was V2022-01-01T00:00:00Z2022 Mar2025-04-04T07:55:11.378Z2025-04-04T07:55:11.378ZS-EPMC88835913523770010.1093/ofid/ofab595